AN2 Therapeutics, Inc.

ANTX chart

AN2 Therapeutics, Inc. news

• AN2 Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

  TradingView · Nov 10, 6:59 AM EST

• AN2 Therapeutics Releases Q3 2026 Financial Results

  AlphaStreet · Nov 9, 3:03 PM EST

• AN2 Therapeutics at Guggenheim conference: pipeline bets on 2027 data By Investing.com

  Investing.com India · Nov 9, 10:10 AM EST

• AN2 Therapeutics 3Q Loss/Shr 17c >ANTX

  Moomoo · Nov 9, 9:52 AM EST

• Form 8K AN2 Therapeutics Inc For: 9 November By Investing.com

  Investing.com Nigeria · Nov 9, 9:37 AM EST

• AN2 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

  www.marketscreener.com · Nov 9, 9:36 AM EST

• AN2 Therapeutics Reports Q3 2026 Earnings: Net Loss of $8.0 Mill

  GuruFocus · Nov 9, 9:26 AM EST

• AN2 Therapeutics Q3 Loss Narrows to $8.0M; PV Phase 2 Cleared in All Jurisdictions

  Minichart · Nov 9, 8:31 AM EST

• AN2 Therapeutics, Inc. (ANTX) stock price, news, quote and history

  Yahoo Finance Australia · Nov 9, 7:37 AM EST

• AN2 Therapeutics, Inc. (ANTX) Tops Q3 EPS by 5c

  StreetInsider · Nov 9, 7:36 AM EST

• AN2 Therapeutics Reports $8.0 Million Q3 Net Loss, Advances Pipeline

  TradingView · Nov 9, 7:33 AM EST

• Epetraborole trial receives clearance in all planned jurisdictions for AN2 Therapeutics (ANTX).

  Stock Titan · Nov 9, 7:32 AM EST

AN2 Therapeutics, Inc. key financials

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 10-Q10-Q2026-11-09
• 8-K8-K2026-11-09
• 10-Q10-Q2026-08-11
• 8-K8-K2026-08-11
• 8-K8-K2026-06-09
• 8-K8-K2026-06-04
• 10-Q10-Q2026-05-11
• 8-K8-K2026-05-11
• DEF 14ADEF 14A2026-04-22
• 8-K8-K2026-04-09
• 8-K8-K2026-03-20
• 10-K10-K2026-03-17

About AN2 Therapeutics, Inc.

Ticker

ANTX (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

Menlo Park, CA

Incorporated in

DE

Fiscal year end

December 31

SEC CIK

1880438

Frequently asked questions